المؤلفون: Monk, B. J., Barretina-Ginesta, M. P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M. R., McCormick, C. C., Lorusso, D., Moore, R. G., Freyer, G., O'Cearbhaill, R. E., Heitz, F., O'Malley, D. M., Redondo, A., Shahin, M. S., Vulsteke, C., Bradley, W. H., Haslund, C. A., Chase, D. M., Pisano, C., Holman, L. L., Pérez, M. J. Rubio, DiSilvestro, P., Gaba, L., Herzog, T. J., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I. A., González-Martín, A.

المصدر: Monk , B J , Barretina-Ginesta , M P , Pothuri , B , Vergote , I , Graybill , W , Mirza , M R , McCormick , C C , Lorusso , D , Moore , R G , Freyer , G , O'Cearbhaill , R E , Heitz , F , O'Malley , D M , Redondo , A , Shahin , M S , Vulsteke , C , Bradley , W H , Haslund , C A , Chase , D M , Pisano , C , Holman , L L , Pérez , M ....

مصطلحات موضوعية: PARP inhibitor, maintenance, niraparib, ovarian cancer, overall survival

وصف الملف: application/pdf

الاتاحة: https://vbn.aau.dk/da/publications/8f91a24a-4389-4030-9596-6587d8907abf
https://doi.org/10.1016/j.annonc.2024.08.2241
https://vbn.aau.dk/ws/files/750687862/Monk_et_al._2024_._Niraparib_first-line_maintenance_therapy_in_patients_with_newly_diagnosed_advanced_ovarian_cancer_-_final_overall_survival_results_from_the_PRIMA-ENGOT-OV26-GOG-3012_trial.pdf
http://www.scopus.com/inward/record.url?scp=85204351787&partnerID=8YFLogxK

المؤلفون: Grisham R., Monk B. J., Van Nieuwenhuysen E., Moore K. N., Fabbro M., O'Malley D. M., Oaknin A., Thaker P., Oza A. M., Colombo N., Gershenson D., Aghajanian C. A., Choi C. H., Lee Y. C., Mirza M. R., Coleman R. L., Cobb L., Harter P., Lustgarten S., Youssoufian H., Banerjee S.

المساهمون: Grisham, R, Monk, B, Van Nieuwenhuysen, E, Moore, K, Fabbro, M, O'Malley, D, Oaknin, A, Thaker, P, Oza, A, Colombo, N, Gershenson, D, Aghajanian, C, Choi, C, Lee, Y, Mirza, M, Coleman, R, Cobb, L, Harter, P, Lustgarten, S, Youssoufian, H, Banerjee, S

مصطلحات موضوعية: Ovarian Cancer

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/39375168; info:eu-repo/semantics/altIdentifier/wos/WOS:001337027300001; journal:INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER; https://hdl.handle.net/10281/524101

الاتاحة: https://hdl.handle.net/10281/524101
https://doi.org/10.1136/ijgc-2024-005919

المؤلفون: Moore K. N., Lorusso D., Oaknin A., Oza A., Colombo N., Van Gorp T., O'Malley D. M., Banerjee S., Murphy C. G., Harter P., Konecny G. E., Pautier P., Method M., Wang Y., Coleman R. L., Birrer M., Matulonis U. A.

المساهمون: Moore, K, Lorusso, D, Oaknin, A, Oza, A, Colombo, N, Van Gorp, T, O'Malley, D, Banerjee, S, Murphy, C, Harter, P, Konecny, G, Pautier, P, Method, M, Wang, Y, Coleman, R, Birrer, M, Matulonis, U

مصطلحات موضوعية: ADC, Antibody-drug conjugate, Folate receptor alpha, Integrated safety, Mirvetuximab soravtansine, Ocular adverse event, Ovarian cancer

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/39461270; info:eu-repo/semantics/altIdentifier/wos/WOS:001347334400001; volume:191; firstpage:249; lastpage:258; numberofpages:10; journal:GYNECOLOGIC ONCOLOGY; https://hdl.handle.net/10281/524099

الاتاحة: https://hdl.handle.net/10281/524099
https://doi.org/10.1016/j.ygyno.2024.10.013

المؤلفون: Van der Kolk, W. L., Van der Zee, A. G. J., Slomovitz, B. M., Baldwin, P. J. W., Van Doorn, H. C., De Hullu, J. A., Van der Velden, J., Gaarenstroom, K. N., Slangen, B. F. M., Kjolhede, P., Brännström, Mats, 1958, Vergote, I., Holland, C. M., Coleman, R., Van Dorst, E. B. L., Van Driel, W. J., Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P. A., Mannel, R. S., Tjiong, M. Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I. B., Monk, B. J., Zanagnolo, V., Tamussino, K., Oonk, M. H. M., Levenback, C. F., Hermans, R. H., Bouda, J., Sharma, A., Luesley, D., Ellis, P., Cruickshank, D. J., Duncan, T. J., Kieser, K., Palle, C., Spirtos, N. M., O'Malley, D. M., Leitao, M. M., Geller, M., Dhar, K., Asher, V., Tobias, D. H., Borgfeldt, C., Lea, J. S., Lood, M., Bailey, J., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K. S., Persson, P., Manchanda, R., Jensen, P., Van Le, L.

المصدر: Gynecologic Oncology. 167(1):3-10

مصطلحات موضوعية: Cancer and Oncology, Cancer och onkologi, Vulvar cancer, Sentinel lymph node, Inguinofemoral lymphadenectomy, Lymph node metastases, Radiotherapy, cancer-patients, Oncology, Obstetrics & Gynecology

URL الوصول: https://gup.ub.gu.se/publication/320870

المؤلفون: Banerjee, S. N., Ring, S., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, Andrew R, Moore, K. N., Rose, P. G., O'Malley, D. M., Chon, H. S., Salinas, E. A., Prendergast, E. N., Lustgarten, S., Rodrigues, M., Gennigens, C., Monk, B. J., Grisham, R. N.

المساهمون: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), London

Relation: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.5515; Ring S, Van Nieuwenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003028.; http://hdl.handle.net/10541/626644; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/626644
https://doi.org/10.1200/JCO.2023.41.16_suppl.5515

المؤلفون: Grisham, R. N., Vergote, I., Banerjee, S., Drill, E., Kalbacher, E., Mirza, M. R., Romero, I., Vuylsteke, P., Coleman, R. L., Hilpert, F., Oza, A. M., Westermann, A., Oehler, M. K., Pignata, S., Aghajanian, C., Colombo, N., Cibula, D., Moore, K. N., Del Campo, J. M., Berger, R., Marth, C., Sehouli, J., O'Malley, D. M., Churruca, C., Kristensen, G., Clamp, Andrew R, Farley, J., Iyer, G., Ray-Coquard, I., Monk, B. J.

المساهمون: Memorial Sloan Kettering Cancer Center, New York, NY, United States

Relation: https://dx.doi.org/10.1158/1078-0432.ccr-23-0621; Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, et al. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Aug 15. PubMed PMID: 37581616. Epub 2023/08/15. eng.; http://hdl.handle.net/10541/626514; Clinical Cancer Research

الاتاحة: http://hdl.handle.net/10541/626514
https://doi.org/10.1158/1078-0432.ccr-23-0621

المؤلفون: O'Malley, D M, Bariani, G M, Cassier, P A, Marabelle, A, Hansen, A R, De Jesus Acosta, A, Miller, W H, Safra, T, Italiano, A, Mileshkin, L, Amonkar, M, Yao, L, Jin, F, Norwood, K, Maio, M

المساهمون: O'Malley, D M, Bariani, G M, Cassier, P A, Marabelle, A, Hansen, A R, De Jesus Acosta, A, Miller, W H, Safra, T, Italiano, A, Mileshkin, L, Amonkar, M, Yao, L, Jin, F, Norwood, K, Maio, M

مصطلحات موضوعية: Advanced endometrial cancer, Health-related quality of life, Microsatellite instability high, Mismatch repair deficiency, Patient-reported outcome, Pembrolizumab

Relation: info:eu-repo/semantics/altIdentifier/pmid/35835611; info:eu-repo/semantics/altIdentifier/wos/WOS:000837233300008; volume:166; issue:2; firstpage:245; lastpage:253; numberofpages:9; journal:GYNECOLOGIC ONCOLOGY; https://hdl.handle.net/11365/1253680; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85134470819

الاتاحة: https://hdl.handle.net/11365/1253680
https://doi.org/10.1016/j.ygyno.2022.06.005

المؤلفون: Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, Andrew R, Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C. C., Goh, J. C., O'Malley, D. M., Goble, S. M., Maloney, L., Ledermann, J. A.

المساهمون: U.S. Oncology Research, The Woodlands, TX

Relation: https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5544; Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301600.; http://hdl.handle.net/10541/625808; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/625808
https://doi.org/10.1200/JCO.2022.40.16_suppl.5544

المؤلفون: Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M

وصف الملف: text

Relation: http://eprints.gla.ac.uk/148540/7/148540.pdf; Coleman, R. L. et al. (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet , 390(10106), pp. 1949-1961. (doi:10.1016/S0140-6736(17)32440-6 ) (PMID:28916367) (PMCID:PMC5901715)

الاتاحة: http://eprints.gla.ac.uk/148540/
http://eprints.gla.ac.uk/148540/7/148540.pdf

المؤلفون: O'Malley D. M., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A. R., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., Swisher E. M., Maloney L., Goble S., Lin K. K., Kwan T., Ledermann J. A., Coleman R. L.

المساهمون: O'Malley, D, Oza, A, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Gancedo, M, Fong, P, Goh, J, Swisher, E, Maloney, L, Goble, S, Lin, K, Kwan, T, Ledermann, J, Coleman, R

مصطلحات موضوعية: Genomic, Ovarian carcinoma, Rucaparib, Safety

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/36273926; info:eu-repo/semantics/altIdentifier/wos/WOS:000929697400002; volume:167; issue:3; firstpage:404; lastpage:413; numberofpages:10; journal:GYNECOLOGIC ONCOLOGY; https://hdl.handle.net/10281/403099; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85140575072

الاتاحة: https://hdl.handle.net/10281/403099
https://doi.org/10.1016/j.ygyno.2022.08.021

المؤلفون: O'Malley, D, Oza, A, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Gancedo, M, Fong, P, Goh, J, Swisher, E, Maloney, L, Goble, S, Lin, K, Kwan, T, Ledermann, J, Coleman, R, O'Malley D. M., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A. R., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., Swisher E. M., Maloney L., Goble S., Lin K. K., Kwan T., Ledermann J. A., Coleman R. L.

مصطلحات الفهرس: Genomic, Ovarian carcinoma, Rucaparib, Safety, info:eu-repo/semantics/article

URL: https://hdl.handle.net/10281/403099
info:eu-repo/semantics/altIdentifier/pmid/36273926
info:eu-repo/semantics/altIdentifier/wos/WOS:000929697400002
volume:167
issue:3
firstpage:404
lastpage:413
numberofpages:10
journal:GYNECOLOGIC ONCOLOGY

المؤلفون: Kwan, T., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, Andrew R, Scambia, G., Leary, A., Holloway, R. W., Amenedo, M., Fong, P. C. C., Goh, J. C., O'Malley, D. M., Maloney, L., Goble, S., Ledermann, J. A., Coleman, R. L.

المساهمون: Clovis Oncology, Inc., Boulder, CO

Relation: https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5537; Kwan T, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean AP, et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC). Vol. 39, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 5537–5537.; http://hdl.handle.net/10541/624852; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/624852
https://doi.org/10.1200/JCO.2021.39.15_suppl.5537

المؤلفون: Waller, D. M., O'Malley, D. M., Gawler, S. C.

المصدر: Conservation Biology, 1987 Dec 01. 1(4), 335-340.

URL الوصول: https://www.jstor.org/stable/2386018

المؤلفون: Weberpals, J., Oza, A., Lorusso, D., Scambia, G., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Clamp, Andrew R, Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., O'Malley, D. M., Armstrong, D. K., Banerjee, S., Garcia-Donas, J., Swisher, E. M., Cameron, T., Maloney, L., Goble, S., Coleman, R. L., Ledermann, J. A.

المساهمون: Ottawa Hospital Research Institute, Ottawa, Canada

Relation: https://dx.doi.org/10.1136/ijgc-2020-IGCS.3; Weberpals J, Oza A, Lorusso D, Scambia G, Aghajanian C, Oaknin A, et al. Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. International Journal of Gynecological Cancer. 2020;30:A2-A3.; http://hdl.handle.net/10541/623861; International Journal of Gynecological Cancer

الاتاحة: http://hdl.handle.net/10541/623861
https://doi.org/10.1136/ijgc-2020-IGCS.3

المؤلفون: O'Malley, D. M., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, Andrew R, Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., Armstrong, D. K., Banerjee, S., Garcia-Donas, J., Swisher, E. M., Cameron, T., Maloney, L., Goble, S., Lin, K. K., Ledermann, J. A., Coleman, R. L.

المساهمون: The Ohio State University, James Cancer Hospital, Columbus, OH, USA

Relation: https://dx.doi.org/10.1016/j.ygyno.2020.06.153; O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3. Gynecologic Oncology. 2020;159:74-5.; http://hdl.handle.net/10541/623506; Gynecologic Oncology

الاتاحة: http://hdl.handle.net/10541/623506
https://doi.org/10.1016/j.ygyno.2020.06.153

المؤلفون: Dean, A., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Colombo, N., Weberpals, J., Clamp, Andrew R, Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., O'Malley, D. M., Cameron, T., Maloney, L., Goble, S., Coleman, R. L., Ledermann, J. A.

المساهمون: Department of Oncology, St John of God Subiaco Hospital, Subiaco, Australia

Relation: https://dx.doi.org/10.1016/j.annonc.2020.08.960; Dean A, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Colombo N, et al. 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology. 2020;31:S620-S1.; http://hdl.handle.net/10541/623482; Annals of Oncology

الاتاحة: http://hdl.handle.net/10541/623482
https://doi.org/10.1016/j.annonc.2020.08.960

المؤلفون: Oaknin A., Oza A. M., Lorusso D., Aghajanian C., Dean A., Colombo N., Weberpals J. I., Clamp A. R., Scambia G., Leary A., Holloway R. W., Amenedo Gancedo M., Fong P. C., Goh J. C., O'Malley D. M., Armstrong D. K., Banerjee S., Garcia-Donas J., Swisher E. M., Cameron T., Maloney L., Goble S., Ledermann J. A., Coleman R. L.

المساهمون: Oaknin, A, Oza, A, Lorusso, D, Aghajanian, C, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Amenedo Gancedo, M, Fong, P, Goh, J, O'Malley, D, Armstrong, D, Banerjee, S, Garcia-Donas, J, Swisher, E, Cameron, T, Maloney, L, Goble, S, Ledermann, J, Coleman, R

مصطلحات موضوعية: clinical trial, gynecological oncology, medical oncology, target therapy, women's cancer

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/34549539; info:eu-repo/semantics/altIdentifier/wos/WOS:000697615600001; volume:10; issue:20 (October 2021); firstpage:7162; lastpage:7173; numberofpages:12; journal:CANCER MEDICINE; http://hdl.handle.net/10281/331133; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115241196

الاتاحة: http://hdl.handle.net/10281/331133
https://doi.org/10.1002/cam4.4260

المؤلفون: Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., Lorusso D.

المساهمون: Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D

مصطلحات موضوعية: Lurbinectedin, Ovarian cancer, Phase III study, Platinum-resistant

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/34521554; info:eu-repo/semantics/altIdentifier/wos/WOS:000714728500004; volume:163; issue:2; firstpage:237; lastpage:245; numberofpages:9; journal:GYNECOLOGIC ONCOLOGY; https://hdl.handle.net/10281/403103; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85114724063

الاتاحة: https://hdl.handle.net/10281/403103
https://doi.org/10.1016/j.ygyno.2021.08.032

المؤلفون: Clamp A. R., Lorusso D., Oza A. M., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Scambia G., Leary A., Holloway R. W., Amenedo Gancedo M., Fong P. C., Goh J. C., O'Malley D. M., Armstrong D. K., Banerjee S., Garcia-Donas J., Swisher E. M., Cameron T., Goble S., Coleman R. L., Ledermann J. A.

المساهمون: Clamp, A, Lorusso, D, Oza, A, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Scambia, G, Leary, A, Holloway, R, Amenedo Gancedo, M, Fong, P, Goh, J, O'Malley, D, Armstrong, D, Banerjee, S, Garcia-Donas, J, Swisher, E, Cameron, T, Goble, S, Coleman, R, Ledermann, J

مصطلحات موضوعية: ovarian cancer

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/34103386; info:eu-repo/semantics/altIdentifier/wos/WOS:000672330600001; volume:31; issue:7; firstpage:949; lastpage:958; numberofpages:10; journal:INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER; http://hdl.handle.net/10281/327591; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107749899

الاتاحة: http://hdl.handle.net/10281/327591
https://doi.org/10.1136/ijgc-2020-002240

المؤلفون: Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D, Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., Lorusso D.

مصطلحات الفهرس: Lurbinectedin, Ovarian cancer, Phase III study, Platinum-resistant, info:eu-repo/semantics/article

URL: https://hdl.handle.net/10281/403103
info:eu-repo/semantics/altIdentifier/pmid/34521554
info:eu-repo/semantics/altIdentifier/wos/WOS:000714728500004
volume:163
issue:2
firstpage:237
lastpage:245
numberofpages:9
journal:GYNECOLOGIC ONCOLOGY